Stock 600420 SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
10.88 CNY +2.93% Intraday chart for Shanghai Shyndec Pharmaceutical Co., Ltd. +3.42% +11.13%
04-29 Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-16 Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 9,346 13,130 14,592 -
Enterprise Value (EV) 1 9,346 13,130 14,592 14,592
P/E ratio 14.9 x 18 x 17 x 14.7 x
Yield - 1.02% 13.8% 16.5%
Capitalization / Revenue - 1.09 x 1.09 x 0.99 x
EV / Revenue - 1.09 x 1.09 x 0.99 x
EV / EBITDA - - - -
EV / FCF - - - -
FCF Yield - - - -
Price to Book - 1.06 x 1.31 x 1.26 x
Nbr of stocks (in thousands) 1,026,983 1,341,173 1,341,173 -
Reference price 2 9.100 9.790 10.88 10.88
Announcement Date 23-01-13 24-03-29 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 - 12,070 13,353 14,688
EBITDA - - - -
EBIT - - - -
Operating Margin - - - -
Earnings before Tax (EBT) - - - -
Net income 1 626.6 691.9 863 996
Net margin - 5.73% 6.46% 6.78%
EPS 2 0.6101 0.5433 0.6400 0.7400
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share 2 - 0.1000 1.500 1.800
Announcement Date 23-01-13 24-03-29 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2,908 3,123 3,238 3,433 3,339
EBITDA - - - - -
EBIT - - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS 2 0.0900 0.2470 0.1500 0.2100 0.1900
Dividend per Share - - - - -
Announcement Date 24-03-29 24-04-29 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - 6.02% 7.9% 8.8%
ROA (Net income/ Total Assets) - - 4.5% 4.9%
Assets 1 - - 19,178 20,327
Book Value Per Share 2 - 9.240 8.330 8.640
Cash Flow per Share 2 - 1.280 0.6800 0.8000
Capex - - - -
Capex / Sales - - - -
Announcement Date 23-01-13 24-03-29 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10.88
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.13% 2.02B
MERCK KGAA Stock Merck KGaA
+7.01% 69.91B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.55% 9.24B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-12.75% 5.05B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.38% 4.47B
YUHAN CORPORATION Stock Yuhan Corporation
+5.23% 3.92B
INDIVIOR PLC Stock Indivior PLC
+23.71% 2.44B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.05% 2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.72% 2.23B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+4.60% 1.66B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600420 Stock
  4. Financials Shanghai Shyndec Pharmaceutical Co., Ltd.